X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.prnewswire.com/news-releases/eisai-to-present-data-on-robust-neurology-portfolio-at-the-76th-american-academy-of-neurology-aan-annual-meeting-302114979.html
https://www.prnewswire.com/news-releases/eisai-to-present-latest-dayvigo-lemborexant-civ-data-at-35th-annual-virtual-sleep-2021-meeting-301308305.html
https://www.newswire.ca/fr/news-releases/sante-canada-autorise-dayvigo-lemborexant--876441695.html
https://www.prnewswire.com/news-releases/eisai-presents-new-analyses-from-phase-3-studies-of-dayvigo-lemborexant-civ-for-the-treatment-of-insomnia-in-adult-patients-at-virtual-sleep-2020-301120401.html
https://www.prnewswire.com/news-releases/eisai-to-present-latest-insomnia-research-including-data-on-new-treatment-dayvigo-lemborexant-civ-at-the-sleep-2020-virtual-conference-301116731.html
https://www.prnewswire.com/news-releases/eisai-to-present-latest-insomnia-research-including-data-on-new-treatment-dayvigo-lemborexant-civ-at-the-sleep-2020-virtual-conference-301116731.html
https://www.prnewswire.com/news-releases/eisai-alzheimers-disease-pipeline-research-to-be-presented-at-virtual-aaic-2020-including-ban2401-and-lemborexant-data-and-a-biomarker-symposium-301099274.html
https://au.finance.yahoo.com/news/eisai-drug-application-house-developed-013300370.html
https://www.biospectrumasia.com/news/25/16235/eisai-to-launch-in-house-developed-new-anti-insomnia-drug-in-japan.html
https://www.prnewswire.com/news-releases/eisai-announces-us-availability-of-dayvigo-lemborexant-civ-a-new-treatment-option-for-adults-with-insomnia-301068256.html
http://www.pharmafile.com/news/537431/mhra-expands-approval-dysport-symptomatic-treatment-focal-spasticity-upper-limbs-paediat
https://www.prnewswire.com/news-releases/pivotal-phase-3-study-of-dayvigo-lemborexant-for-the-treatment-of-insomnia-disorder-published-in-jama-network-open-300979554.html
https://www.prnewswire.com/news-releases/us-fda-approves-eisais-dayvigo-lemborexant-for-the-treatment-of-insomnia-in-adult-patients-300978786.html
https://www.prnewswire.com:443/news-releases/new-data-in-2-oral-and-13-poster-presentations-about-eisais-latest-dementia-pipeline-including-ban2401-elenbecestat-and-lemborexant-to-be-presented-at-alzheimers-association-international-conference-300883623.html
https://www.prnewswire.com/news-releases/extensive-analyses-of-phase-3-data-for-investigational-lemborexant-assess-efficacy-and-safety-profile-for-the-potential-treatment-of-insomnia-in-adults-300865016.html
https://www.prnewswire.com/news-releases/eisai-to-present-eight-lemborexant-posters-at-sleep-2019-meeting-including-new-pooled-analyses-from-phase-3-studies-and-new-phase-1-data-300857374.html
https://www.prnewswire.com/news-releases/eisai-and-purdue-pharma-announce-buy-out-of-purdues-rights-in-worldwide-collaboration-to-develop-and-commercialize-lemborexant-300841417.html
https://www.prnewswire.com/news-releases/eisai-and-purdue-pharma-announce-buy-out-of-purdues-rights-in-worldwide-collaboration-to-develop-and-commercialize-lemborexant-300841417.html
https://www.biospectrumasia.com/news/33/13000/fda-accepts-nda-for-lemborexant-to-treat-insomnia.html
https://www.prnewswire.com/news-releases/eisai-and-imbrium-therapeutics-announce-us-fda-filing-acceptance-of-new-drug-application-for-lemborexant-for-the-treatment-of-insomnia-300809862.html
https://www.biospectrumasia.com/news/25/12963/eisai-submits-marketing-authorization-application-for-insomnia-drug-.html
https://www.biospectrumasia.com/news/25/11898/eisai-purdue-pharma-declare-positive-results-of-sunrise-2-.html
https://www.biospectrumasia.com/news/25/11898/eisai-purdue-pharma-declare-positive-results-of-sunrise-2-.html
https://www.fiercebiotech.com/biotech/eisai-purdue-reveal-eye-opening-data-for-sleep-drug-lemborexant
https://www.biospectrumasia.com/news/25/10944/eisai-purdue-to-present-latest-clinical-data-on-lemborexant-.html
https://www.prnewswire.com/news-releases/eisai-and-purdue-pharma-announce-key-phase-1-clinical-studies-of-lemborexant-to-be-presented-at-the-32nd-annual-sleep-meeting-300652696.html
Market Place
Share 
